← Back to headlines
FDA Extends Review of Exelixis' Colorectal Cancer Drug
The US Food and Drug Administration has extended its review period for Exelixis' zanzalintinib, a treatment for colorectal cancer, by three months. The delay caused Exelixis stock to fall as investors awaited further regulatory clarity.
11 Sept, 11:50 — 11 Sept, 12:59
The Story
Analyzing sources…
Source Diversity
Source Diversity
Moderate (37/100)3 sources25/33
Spectrum spread— 2/5 buckets covered8/33
Far L
Left
Center2
Center (2)
investing-commorningstar
Right1
Right (1)
seeking-alpha
Far R
Geographic diversity— 1 region4/34
US3
ℹAll sources from US region
Sources
Showing 2 of 3 sources
morningstar1h ago
FDA Extends Review of Exelixis' Zanzalintinib in Colorectal Cancer - Morningstar
FDA Extends Review of Exelixis' Zanzalintinib in Colorectal Cancer Morningstar
Read full article →seeking-alphaMixed31m ago
Exelixis zanzalintinib NDA review extended three months by FDA
Read full article →Coverage Timeline
First report: morningstar · 11 Sept, 11:50|Full coverage: 3 · 1h|Window: 1h
Left-leaningCenterRight-leaning
